HFCAS OpenIR

浏览/检索结果: 共2条,第1-2条 帮助

限定条件        
已选(0)清除 条数/页:   排序方式:
Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations 期刊论文
CHINESE JOURNAL OF CANCER RESEARCH, 2017, 卷号: 29
-
收藏  |  浏览/下载:33/0  |  提交时间:2020/10/26
EGFR MUTATIONS  GEFITINIB TREATMENT  1ST-LINE TREATMENT  OPEN-LABEL  RARE  MULTICENTER  ERLOTINIB  GENE  CHEMOTHERAPY  EFFICACY  Non-small cell lung cancer  EGFR  uncommon mutation  target therapy  
Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice 期刊论文
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2017, 卷号: 18
-
收藏  |  浏览/下载:27/0  |  提交时间:2020/10/26
RANDOMIZED PHASE-III  NEOADJUVANT CHEMOTHERAPY  ENCAPSULATED DOXORUBICIN  1ST-LINE CHEMOTHERAPY  PROGNOSTIC MARKER  PLUS DOCETAXEL  COMBINATION  CYCLOPHOSPHAMIDE  TRASTUZUMAB  PACLITAXEL  Liposomal doxorubicin  Breast cancer  Adjuvant chemotherapy  Therapeutic effect  Toxic and side effects